oral anticoagulants

Widespread Anticoagulation Has Lowered Stroke but Not Intracranial Bleeding in the Very Elderly: Insights from a Danish Nationwide AF Cohort (1999–2022)

By MedXY 11/29/2025

Danish registry data (1999–2022) show large reductions in stroke across age groups with widespread oral anticoagulant (OAC) uptake, but only modest stroke gains and rising intracerebral hemorrhage in patients ≥85 years, highlighting the need for individualized strategies in the very elderly.

Cardiology Clinical Updates news

Continued versus Discontinued Oral Anticoagulant Therapy for Unprovoked Venous Thromboembolism: A Target Trial Emulation and Evidence Synthesis

By MedXY 11/22/2025

Continued oral anticoagulant therapy after ≥90 days for unprovoked VTE significantly lowers recurrence and mortality despite increased bleeding risk, offering a net clinical benefit consistent across anticoagulant types and treatment durations.

Cardiology Specialties

Reevaluating Long-Term Anticoagulation After Atrial Fibrillation Ablation: Insights from the ALONE-AF Randomized Trial

By MedXY 09/01/2025

The ALONE-AF trial reveals that discontinuation of oral anticoagulants post-successful atrial fibrillation ablation may reduce stroke, systemic embolism, and major bleeding compared to continued therapy, informing anticoagulation strategies in selected patients.